Background MMR vaccination is complicated by rare cases of autoimmune purpura or thrombocytopenia in a chronological delay of about 10-24 days, which corresponds to the rise of antibodies (Autret E, 1996; Vlacha V, 1996) . We have demonstrated that in the cases of HIV-1, Parvovirus B19, Chikungunya virus, Leptospirosis, the culprit is an epitope localized on the platelet gpIIIaIIb, centred by a phenylalanine-proline (Tran MKG, ISHEID Toulon 2002); these auto-antibodies are very powerful and induce in mice a thrombocytopenia; allo-immunisation from mother to the newborn has the same epitope on gpIIIaIIb (Brouk H, 2009) . We continue the same direction of research for MMR vaccine.
Methods

Comparison of amino acid sequences between gpIIIaIIb and viruses (measles, mumps and rubella).
Results
There is a molecular mimicry between gpIIb (P08514) and measles virus (strain MVi/Victoria.Aus/12.99) Phosphoprotein P (ABV24494) (Bankamp B, 2008), Table 1 .
Discussion
The occurrence of thrombocytopenia 2 or 3 weeks after MMR vaccination is an auto-immune phenomenon, on a peculiar genetic background prone to make auto-antibodies against phenylalanine-proline containing epitopes. MMR vaccine must be avoided in these patients with idiopathic thrombocytopenia (Drachtman RA, 1994) . The chronological argument is by itself convincing and confirmed here by the biological finding of the causal epitope on platelet. Thus we must be very cautious in presence of a MMR vaccine clinical auto-immune complication (such as autism) (Wakefield AJ) and not discard it as a simple coincidence, but rather try to elucidate its mechanism and genetics (HLA-DR4). The gpIIIaIIb epitope may serve as a chelating hapten for treatment. 
